)
)
Ben Doak
Ben oversees the commissioning of all licensed ATMPs recommended by NICE in England to ensure timely access by patients. Ben also chairs the England Department of Health and Social Care’s subgroup on data for ATMPs, is a member of the Department’s apheresis working group and is leading NHS England’s activity on developing an operational framework for the delivery of individualised genetic therapies.
Since commencing his current role in 2020, Ben has overseen the expansion of CAR-T services in the England as well supporting access to ATMPs such as Casgevy for transfusion-dependent beta-thalassaemia and sickle cell disease, Hemgenix for haemophilia B and Zolgensma for spinal muscular atrophy. He maintains an active interest in horizon scanning of ATMPs and other innovative treatments.
Sessions
-
Getting Commissioned ATMPs to Patients: Key Insights28-Jan-2026Advanced Therapies Stage